Supernus Pharmaceuticals Shares Are Trading Lower After the Company Announced the FDA Has Issued a Complete Response Letter in Response to the Company's New Drug Application for SPN-830.
Supernus Pharmaceuticals Shares Are Trading Lower After the Company Announced the FDA Has Issued a Complete Response Letter in Response to the Company's New Drug Application for SPN-830.
Supernus Pharmicals宣佈美國食品藥品管理局已針對該公司的 SPN-830 新藥申請發佈了完整的回覆信，此後，該公司股價走低。
Supernus Pharmaceuticals Shares Are Trading Lower After the Company Announced the FDA Has Issued a Complete Response Letter in Response to the Company's New Drug Application for SPN-830.
Supernus Pharmicals宣佈美國食品藥品管理局已針對該公司的 SPN-830 新藥申請發佈了完整的回覆信，此後，該公司股價走低。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。